Compare IPHA & GORO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPHA | GORO |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | France | United States |
| Employees | 163 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.5M | 212.0M |
| IPO Year | N/A | 2010 |
| Metric | IPHA | GORO |
|---|---|---|
| Price | $1.76 | $1.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $5.75 | $1.63 |
| AVG Volume (30 Days) | 134.2K | ★ 1.6M |
| Earning Date | 03-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.80 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $99,759,000.00 |
| Revenue This Year | $180.36 | $25.99 |
| Revenue Next Year | N/A | $5.78 |
| P/E Ratio | ★ N/A | $44.50 |
| Revenue Growth | N/A | ★ 51.78 |
| 52 Week Low | $1.18 | $0.43 |
| 52 Week High | $2.63 | $1.87 |
| Indicator | IPHA | GORO |
|---|---|---|
| Relative Strength Index (RSI) | 54.22 | 52.15 |
| Support Level | $1.72 | $1.23 |
| Resistance Level | $2.32 | $1.49 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 40.00 | 79.17 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.